Zepbound vs Wegovy: Dose, Approved Uses and Cost Compared

Zepbound and Wegovy get compared constantly, and most of that comparison collapses into "which one works better." That's one real question, but it isn't the only one — the two brands are also approved for genuinely different things, and the FDA-approved use list tells a story the weight-loss percentage alone does not.

They are different molecules, not different doses of the same drug

Wegovy is semaglutide, made by Novo Nordisk. Zepbound is tirzepatide, made by Eli Lilly — a dual GIP/GLP-1 receptor agonist, mechanistically distinct from semaglutide's single-receptor action. For the full molecule-level efficacy-versus-price breakdown across both brand and compounded routes, see semaglutide vs tirzepatide; this piece stays specifically on the two brand-name products.

What is each one approved for?

This is the part the "which is stronger" framing misses entirely. Per its FDA prescribing information, Wegovy is approved for three separate indications: reducing major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight; weight reduction in adults and pediatric patients 12 and older with obesity (or adults with overweight plus a weight-related comorbidity); and, more recently, treating noncirrhotic MASH (metabolic dysfunction-associated steatohepatitis, formerly NASH) with moderate to advanced liver fibrosis¹. Zepbound, by contrast, is approved for two: weight reduction in adults with obesity or overweight plus a comorbidity, and treating moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity² — an indication established by the dedicated SURMOUNT-OSA trial, which found tirzepatide reduced the apnea-hypopnea index significantly more than placebo in adults with obesity and moderate-to-severe OSA³; see Zepbound for sleep apnea for what that trial actually measured and why it can matter for insurance coverage. Neither drug is simply "the stronger one" — they carry different approved uses because they were studied for different things, and if you have cardiovascular disease, liver fibrosis, or sleep apnea specifically, that list matters more than the average weight-loss number.

Which one causes more weight loss?

Where the two are studied directly against each other, the evidence points one way. SURMOUNT-5, a randomized head-to-head trial in adults with obesity, compared tirzepatide directly against semaglutide 2.4 mg — Wegovy's own labeled dose — and found tirzepatide produced significantly greater average weight loss, with broadly comparable safety and tolerability between the two⁴. That is a genuine apples-to-apples comparison, not an inference from two separate trials. See GLP-1 side effects for what "comparable safety" means in practice — mostly overlapping GI-effect profiles — and the dosing and titration schedule for exactly how each drug ramps up (Zepbound tops out at 15 mg weekly; Wegovy's standard maintenance is 2.4 mg, with a labeled 7.2 mg ceiling for added weight loss in patients who've tolerated 2.4 mg).

How much do Zepbound and Wegovy cost without insurance?

Both manufacturers now sell direct to self-pay patients well below the old retail list price — a very different picture from the diabetes-branded version of semaglutide, Ozempic, which carries no weight-management indication at all and a different coverage story entirely; see Ozempic vs Wegovy for why that label difference matters more than people assume. On Novo Nordisk's NovoCare page, read in October 2026, self-pay Wegovy pens cost $349 a month at every dose up to 2.4 mg and $399 at the 7.2 mg dose, and new patients pay $199 a month for the first two fills at 0.25 mg and 0.5 mg⁵. Eli Lilly's Zepbound savings page lists self-pay Zepbound in the KwikPen or vials starting at $299 a month for the 2.5 mg starting dose, with higher prices at higher doses⁶. Both are the genuine FDA-approved product, not a compounded copy, and our full cash-pay cost breakdown covers the other routes. Zepbound's cost, isolated breaks that down further against compounded tirzepatide and our brand-access partners.

How to actually decide

Start with the approved-use list, not the weight-loss percentage: if you have established cardiovascular disease, advanced liver fibrosis, or moderate-to-severe sleep apnea alongside obesity, that narrows the choice before efficacy even enters the conversation. If none of those apply and average weight loss is the deciding factor, SURMOUNT-5's head-to-head result favors tirzepatide, at a comparable brand self-pay price to Wegovy. Either way, price your actual year — not the intro month — using the true monthly cost guide and the cost calculators, and check both against compounded alternatives if the brand price is the barrier. The labels and trials behind this comparison are indexed in our research library. Not medical advice — see our medical disclaimer and discuss your own history with a clinician before choosing between them.